Posted by Michael Wonder on 07 Feb 2024
Olaparib in combination with abiraterone acetate for the treatment of patients with hormone relapsed metastatic prostate cancer
7 February 2024 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) in combination with abiraterone acetate for the treatment of patients with hormone relapsed metastatic prostate cancer.
Olaparib, when used in combination with abiraterone acetate and prednisone or prednisolone is recommended for the treatment of adults with hormone relapsed metastatic prostate cancer who cannot have or do not want chemotherapy only AstraZeneca provides it according to the commercial arrangements.
